EUCTR2016-002267-33-GB进行中（未招募）1 期
A parallel group phase I/II marker lesion study to assess the safety, tolerability and efficacy of intravenous or intravesical pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer - PemBla
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to be eligible for participation in this trial, the subject must:
- •1.Be willing and able to provide written informed consent for the trial and comply with the protocol scheduled follow-up visits and examinations for the duration of the study
- •2.Be equal to or over 18 years of age on day of signing informed consent
- •3.Have recurrent NMIBC for which adjuvant treatment post TURBT would be a reasonable treatment option
- •4.Main study only:
- •a.Have recurrent, multiple (minimum 2) tumours consistent with NMIBC
- •b.Have at least one lesion of between 5-10mm in size clinically that can be left un-resected at TURBT as the marker lesion
- •c.Have histologically confirmed low grade transitional cell NMIBC at original and any subsequent diagnosis
- •5.Have a normal upper urinary tract (as evidenced by ultrasound or CT urography within 2 years prior to randomisation) and no evidence of tumour in prostatic urethra at flexible cystoscopy
- •6.Have a performance status of 0 or 1 on the ECOG Performance Scale
- •7.Have adequate organ function as defined in the table below:
- •Lab Test Value required
- •Haemoglobin (Hb) = 9 g/dL without transfusion or EPO dependency
- •Absolute neutrophil count = 1.5 x 109/L
- •Platelet count = 100 x 109/L
- •Total bilirubin = 1.5 times the upper limit of normal (ULN) or direct bilirubin = ULN for subjects with total bilirubin levels > 1.5 x ULN
- •Serum alanine aminotransferase (ALT) and/or serum aspartate aminotransferase (AST) = 2.5 x ULN
- •Serum creatinine OR
- •Measured or calculated creatinine clearancea = 1.5 x ULN OR
- •= 60ml/min for subject with creatinine levels > 1.5 x institutional ULN
- •Albumin= 25g/L
- •International Normalized Ratio (INR) or Prothrombin Time (PT) and
- •Activated Partial Thromboplastin Time (aPTT)= 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or APTT is within therapeutic range of intended use of anticoagulants
- •8.Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- •9.Both male and female subjects of childbearing potential (Section 5.1) must be willing to use an adequate method of contraception as outlined in section 5.1 for the course of the study and until 120 days after the last dose of the study medication
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 28
排除标准
- •he subject must be excluded from participating in the trial if the subject:
- •1.Has received prior radiotherapy to the pelvis
- •2.Has significant urinary incontinence or known bladder instability
- •3.Main study only:
- •a.Has more than 2 out of 3 of the following present at the current time:
- •i.=8 tumours
- •ii.Tumour =3cm in size
- •iii.Frequent recurrence (>1/year)
- •b.Has a previous history of any of the following: T1 tumour, high grade/G3 tumour, carcinoma in situ, multiple recurrent large (>3cm) Ta, G1 or G2 tumours.
- •c.Had a primary tumour of unknown pathological stage or grade
- •d.Has disease for which resection of all visible tumours is not possible
- •4.Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 28 days of the first dose of trial treatment
- •5.Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Subjects requiring use of inhaled or intranasal corticosteroids or local steroid injections would not be excluded
- •6.Has a known history of active TB
- •7.Has received intravesical BCG treatment within 30 days prior to the first dose of trial treatment
- •8.Has hypersensitivity to pembrolizumab or any of its excipients
- •9.Has had treatment with any other anti-cancer monoclonal antibody within 28 days prior to enrolment or who has not recovered (i.e. = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
- •10.Has had treatment with prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of administration of study drug or who has not recovered (i.e. = Grade 1 or at baseline) from adverse events due to a previously administered agent.)
- •11.Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
- •12.Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurological symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for a t least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability
- •13.Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin or physiologic corticosteroids replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
- •14.Has a known history of, or any evidence of active, non-infectious pneumonitis
- •15.Has an active or intractable infection requiring systemic therapy
- •16.Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of th
研究者
相似试验
终止
1 期
Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)Non-muscle Invasive Bladder Cancer (NMIBC)NCT03167151University of Oxford6
进行中（未招募）
不适用
A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-DEKeyNeurotek Pharmaceuticals AG108
进行中（未招募）
不适用
A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-CZKeyNeurotek Pharmaceuticals AG108
已完成
不适用
Randomized Parallel Group Phase II Clinical Study of Sorafenib/Interferon Combination Therapy and Sunitinib Monotherapy for Advanced Renal Cell CarcinomaAdvanced renal cell carcinomaJPRN-UMIN000001995Osaka Urological Oncology Research Group200
进行中（未招募）
不适用
A double-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-BEKeyNeurotek Pharmaceuticals AG108